Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients with Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results from the Randomized SPIRIT-H2H Trial

Ixekizumab (IXE)-treated patients achieved significantly greater simultaneous PASI100 and ACR50 responses through W52 versus adalimumab (ADA)-treated, confirming IXE as an efficacious and safe treatment. This study investigated the efficacy and safety of IXE and ADA in the subgroup of patients with PsA and moderate-to-severe PsO through W52.

A comparison of the results of this analysis with those of other studies confirms the efficacy of IXE in treating nail PsO in patients with moderate-to-severe PsO, irrespective of concomitant active PsA. These results increase awareness of available treatment options and inform evidence-based clinical decisions for patients with active PsA and moderate-to-severe PsO.